Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Supporting Vidofludimus Calcium Through Pivotal Development – NEW YORK, April 28, 2026 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael A. Panzara, M.D.